US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Forensic psychiatrist reveals the different types of stalkers
Stalking has been in the spotlight recently thanks to the smash hit success of Netflix drama Baby Re2024-05-21China's consumption gains steam as shopping, tourism, catering rebound
Though the Spring Festival is still a few days away, shopping malls in the city of Baoding, north Ch2024-05-21Texas Rangers score 10 runs in second inning, beat Oakland Athletics 15
OAKLAND, Calif. (AP) — Marcus Semien had four hits and five RBIs, and the Texas Rangers scored 10 ti2024-05-21World champions aim to refresh records in Xiamen
With the 2024 Diamond League just two days away, high jumper Hamish Kerr and discus thrower Laulauga2024-05-21- ST. PETERSBURG, Fla. (AP) — The Tampa Bay Rays placed opening-day starter Zach Eflin on the 15-day i2024-05-21
On the field at least, the Nationals and Orioles have had a pretty friendly rivalry
WASHINGTON (AP) — Dave Martinez was asked about the rivalry between the Nationals and Orioles — spec2024-05-21
atest comment